Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHA NYSEAMERICAN:MAIA NASDAQ:TVGN NASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.11-1.9%$1.95$1.29▼$3.51$198.20M0.2213,670 shs3,514 shsMAIAMAIA Biotechnology$1.58+3.9%$1.76$1.40▼$3.74$46.07M0.01539,359 shs101,737 shsTVGNSemper Paratus Acquisition$0.99-0.7%$1.20$0.26▼$3.09$183.88M-0.77610,717 shs281,649 shsVTYXVentyx Biosciences$2.72+3.4%$2.46$0.78▼$3.39$187.15M0.971.17 million shs287,931 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma-1.86%-4.09%+15.87%-6.22%-1.63%MAIAMAIA Biotechnology+3.95%-8.14%-14.59%-23.30%-46.44%TVGNSemper Paratus Acquisition-0.73%-8.09%-20.27%-5.47%+76.93%VTYXVentyx Biosciences+3.42%-10.53%+29.28%+124.79%+30.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIPHAInnate Pharma2.3526 of 5 stars3.75.00.00.00.01.70.0MAIAMAIA Biotechnology1.6881 of 5 stars0.05.00.00.02.43.30.0TVGNSemper Paratus Acquisition3.5042 of 5 stars3.53.00.00.01.82.50.0VTYXVentyx Biosciences2.7895 of 5 stars3.42.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 3.33Buy$11.00421.33% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ATVGNSemper Paratus Acquisition 3.00Buy$10.00907.46% UpsideVTYXVentyx Biosciences 2.75Moderate Buy$10.00267.65% UpsideCurrent Analyst Ratings BreakdownLatest MAIA, IPHA, VTYX, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/18/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/10/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/12/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$21.77M8.93N/AN/A$0.11 per share19.18MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.14 per shareN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/A($0.09) per shareN/AVTYXVentyx BiosciencesN/AN/AN/AN/A$3.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)MAIAMAIA Biotechnology-$23.25M-$1.38N/AN/AN/AN/A-474.86%-146.56%8/8/2025 (Estimated)TVGNSemper Paratus Acquisition-$13.73MN/A0.00∞N/AN/AN/A-934.56%N/AVTYXVentyx Biosciences-$135.12M-$1.75N/AN/AN/AN/A-47.45%-43.49%8/14/2025 (Estimated)Latest MAIA, IPHA, VTYX, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VTYXVentyx Biosciences-$0.45N/AN/AN/AN/AN/A8/8/2025Q2 2025MAIAMAIA Biotechnology-$0.24N/AN/AN/AN/AN/A5/8/2025Q1 2025VTYXVentyx Biosciences-$0.48-$0.39+$0.09-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate Pharma2.522.602.60MAIAMAIA BiotechnologyN/A2.352.35TVGNSemper Paratus AcquisitionN/A0.350.35VTYXVentyx BiosciencesN/A19.5719.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%MAIAMAIA Biotechnology5.65%TVGNSemper Paratus AcquisitionN/AVTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%MAIAMAIA Biotechnology32.32%TVGNSemper Paratus Acquisition73.24%VTYXVentyx Biosciences14.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableMAIAMAIA Biotechnology930.31 million20.51 millionNot OptionableTVGNSemper Paratus Acquisition3183.89 million49.21 millionN/AVTYXVentyx Biosciences3071.16 million58.22 millionOptionableMAIA, IPHA, VTYX, and TVGN HeadlinesRecent News About These CompaniesShort Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%August 2 at 1:59 PM | marketbeat.comShort Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Rises By 69,900.0%August 2 at 2:07 AM | americanbankingnews.comMonaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)July 30, 2025 | marketbeat.comIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 10, 2025 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comVentyx Biosciences' Study of VTX3232 Met Safety, Tolerability ObjectivesJune 17, 2025 | marketwatch.comVentyx says Parkinson’s disease drug hit main goal in small mid-stage trialJune 17, 2025 | msn.comVentyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial ResultsJune 17, 2025 | msn.comVentyx Biosciences stock trades flat despite positive parkinson’s drug trial dataJune 17, 2025 | investing.comVentyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's DiseaseJune 17, 2025 | quiverquant.comQVentyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's DiseaseJune 17, 2025 | globenewswire.comVentyx Biosciences reports annual meeting resultsJune 12, 2025 | investing.comVentyx Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comVentyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate ProgressMay 8, 2025 | globenewswire.comWhy Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%May 7, 2025 | aaii.comAGreat week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous yearMay 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, IPHA, VTYX, and TVGN Company DescriptionsInnate Pharma NASDAQ:IPHA$2.11 -0.04 (-1.86%) Closing price 08/4/2025 03:59 PM EasternExtended Trading$2.12 +0.01 (+0.47%) As of 08/4/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.MAIA Biotechnology NYSEAMERICAN:MAIA$1.58 +0.06 (+3.95%) Closing price 08/4/2025 04:10 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 08/4/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Semper Paratus Acquisition NASDAQ:TVGN$0.99 -0.01 (-0.73%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.25%) As of 08/4/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Ventyx Biosciences NASDAQ:VTYX$2.72 +0.09 (+3.42%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$2.72 0.00 (0.00%) As of 08/4/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
